<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00380887</url>
  </required_header>
  <id_info>
    <org_study_id>0713E1-133, 0713E1-135</org_study_id>
    <nct_id>NCT00380887</nct_id>
  </id_info>
  <brief_title>Study Comparing Four New Formulations for Premarin in Healthy Postmenopausal Women</brief_title>
  <official_title>An Open-Label, Single-Dose, Randomized, 4-Period, Partial Crossover Bioequivalence/Bioavailability Study Among Four New Formulations of Premarin 0.45 mg/Medroxyprogesterone Acetate (MPA) 1.5 mg Compared With a Reference Formulation of Premarin/MPA (Prempro) 0.45 mg/1.5 mg in Healthy Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine bioequivalence and bioavailability of four
      different Premarin/MPA test formulations versus the current formulation for Prempro.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Screening</primary_purpose>
    <observational_model>Defined Population</observational_model>
    <time_perspective>Cross-Sectional, Prospective</time_perspective>
  </study_design_info>
  <enrollment>54</enrollment>
  <condition>Postmenopause</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Premarin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy postmenopausal women aged 35 to 70 years

          2. Nonsmoker or smoker of less than 10 cigarettes per day

        Exclusion Criteria:

          1. History or presence of clotting disorders

          2. History or presence of cancer

          3. Presence of HIV, hepatitis B or hepatitis C

          4. History of drug or alcohol abuse
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <verification_date>September 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2006</study_first_submitted>
  <study_first_submitted_qc>September 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2006</study_first_posted>
  <last_update_submitted>September 26, 2006</last_update_submitted>
  <last_update_submitted_qc>September 26, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2006</last_update_posted>
  <keyword>bioavailability</keyword>
  <keyword>bioequivalence</keyword>
  <keyword>marketed product</keyword>
  <keyword>Premarin</keyword>
  <keyword>Medroxyprogesterone acetate</keyword>
  <keyword>MPA</keyword>
  <keyword>Postmenopausal</keyword>
  <keyword>vasomotor symptoms</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Medroxyprogesterone</mesh_term>
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
    <mesh_term>Estrogens, Conjugated (USP)</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

